Cytomegalovirus retinitis in post HAART era in the north eastern India

Rajkumari Vidyarani Devi1,*, Kamson Anthony2, Meirenbam Ranjana3, Rajkumar Victor4

1Associate Professor, 2Assistant Professor, 3,4Senior Resident, Dept. of Ophthalmology, Jawaharlal Nehru Institute of Medical Sciences, Imphal, Manipur, India

*Corresponding Author:
Email: dvvidya777@gmail.com

Abstract
Context: HIV prevalence in India is estimated at 0.26% in 2015 with 0.30% among males and at 0.22% among females. Manipur being the highest estimated adult HIV prevalence among all states/UTs (1.15%) in India, Cytomegalovirus (CMV) retinitis and its consequent blindness is still a major challenge demanding early diagnosis and treatment.

Aims: Prevalence of CMV retinitis between the groups of AIDS patients according to their different levels of CD4 T lymphocyte counts

Settings and Design: Retrospective, descriptive study.

Materials and Methods: A total of 682 HIV patients with mean age of 33 years were evaluated. CD4 count and treatment status including best corrected visual acuity and examination of anterior and posterior segment by slit lamp biomicroscope, IDO and fundus photography were done. Confirmed cases of CMV retinitis was excluded from other HIV retinopathy.

Statistical Analysis Used: by using Chi (χ²) square test and simple Statistical tools

Results: Of the 682 person examined CMV retinitis was diagnosed in 24 patients, of which 20 patients were on ART. Prevalence of CMV retinitis in the study was 3.51%. Three cases (2.6%) of CMV retinitis out of 122 patients were observed within CD4 count between 100-299 cells/µl. Nine cases (7.6%) of CMV retinitis were observed out of 71 patients with CD4 count between 50-99 cell/µl. 12 cases (11.2%) of CMV retinitis was diagnosed out of 107 patients with CD4 count < 50 cells/µl. Bilateral CMV retinitis was seen in four patients (0.6%). Optic neuritis was seen in one patient.

Conclusions: Prevalence of CMV Retinitis is common in patients with CD4+ T lymphocytes < 50 cells/µl. Ocular symptoms and poor visual acuity may be misleading as sole criteria indicates the presence of CMV retinitis and advocate a systemic screening of all HIV patients with CD4 count < 100 cells/µl to detect the ocular changes due to CMV retinitis for early prevention from severe visual impairment.

Keywords: HIV/AIDS, Cytomegalovirus retinitis, CD 4 T lymphocyte, HAART.

Introduction
According to India HIV Estimation 2015 report, the prevalence of HIV/AIDS among adult (15-49 years) in India is estimated at 0.26% (0.22%-0.32%) in 2015 with 0.30% among males and at 0.22% among females.1

Manipur is a tiny state in the north eastern India bordering Myanmar and lie between 23.83 degree and 25.68 degree north latitude and 93.03 degree and 94.78 degree east, longitude. It has the highest estimated adult HIV prevalence among all states/UTs (1.15%) in India followed by Mizoram (0.80%) and Nagaland (0.78%). Though declining trends in adult HIV prevalence are sustained in all of the high prevalence States.4

The pattern of HIV transmission in Manipur was initially through sharing of needles and syringes among injecting drug users (IDUs).2 Further more and more female sex partners of IDUs are infected with HIV leading to an increase spread of HIV among women with an estimated 80% or more of the women acquired HIV infection from their husbands.3

Ever since the first report on the ocular manifestations of AIDS by Holland et al in 1983, subsequent studies have described several HIV/AIDS related conditions in the eye and the orbit. Of the spectrum of opportunistic ocular infection, Cytomegalovirus (CMV) retinitis is the leading cause of blindness in HIV/AIDS patients.5

CMV (Human Herpesvirus-5) is a large genomic virus of herpesviruses family which causes influenza-like symptom in immunocompetent individuals and remains latent. However in immunocompromised patients such as HIV/AIDS it causes non-traumatic granulomatous infection and retinitis potentially leading to visual loss.3 Studies have indicated the high prevalence of CMV retinitis among individuals with CD4+ T lymphocytes counts less than 100 cells/µl.6

There are variation in the incidence of CMV retinitis (2 - 20%, India) relating to varied ART regimes, health care access and genetic make-up in developing south east Asian countries.7,8 Also, there are limited epidemiological report on the incidence of CMV retinitis in this part of the country with high burden of HIV/AIDS.

In this retrospective study, 24 CMV retinitis patients out of 682 HIV infected patients admitted and referred from other centers to our institute were analyzed for the spectrum of CMV retinitis including the prevalence, relationship between CMV retinitis and CD4+ T lymphocyte counts.

Materials and Methods
The Study was conducted at department of ophthalmology, Jawaharlal Nehru Institute of Medical Sciences (JNIMS), Imphal from June 2013 - July 2016.
A total of 682 patients with HIV/AIDS patient who were referred to our Outpatient Department from ART centre at JNIMS, Hospitalized patients and other centers were included in this study. The patients were evaluated for CD4+ T Lymphocytes cell count and treatment status. A complete opthalmological examination including refraction with best corrected visual acuity, examination of anterior segment by slit lamp biomicroscope, detail funduscopy was done using Indirect Ophtalmoscopy and 90D biomicroscope and standard 45 degree fundus photo was also recorded for the patients with posterior segment findings. The diagnosis of CMV retinitis was confirmed with typical opthalmoscopic appearance of retinopathy that is yellow-white lesions with granular border or arciform retinal lesion with or without haemorrhage along the vessels.

We have excluded HIV retinopathy, toxoplasmosis retinitis, acute retinal necrosis, progressive outer retinal necrosis etc and all the cases were confirmed by two ophthamlological units.

Statistical Analysis
Statistical analysis were conducted to established the prevalence of CMV retinitis between the groups of HIV/AIDS patients according to their different levels of CD4+ T lymphocyte counts by using Chi(χ²) square test. P values less than<0.05 is considered significant.

Results
Out of the 682 patients, 321 patients were females, 361 patients were male and four transenders patients. The mean age of the study population was 33 year with majority of them belongs to the age group of 30-50 years. Twenty-four patients were diagnosed with CMV retinitis. Of the 24 patients, 20 patients were on ART. The duration of ART treatment ranges from 2 months to 11 years.

![Demographic of the study population](image)

**Fig. 1: Demographic of the study population**

The prevalence of CMV retinitis in this study was 3.51% (24/682). No CMV retinitis was observed in patients with CD4 count of >300 cells/µl. Three (2.6%) CMV retinitis out of 122 patients was seen in patient with CD4 count between 100-299 cells/µl. Nine (7.6%) CMV retinitis were observed out of 71 patients with CD4 count between 50-99 cells/µl. Twelve (11.2%) CMV retinitis out of 107 patients was seen with CD4 T lymphocyte count below 50 cells/µl. Bilateral CMV retinitis was seen in four patients (0.6%). Fulminating type of CMV retinitis was seen in majority of the patients followed by granular and frosted angitis type. Optic neuritis with infiltration around the optic disc was observed in one patient. 115 patients had CD4 count between 300-499 cells/ µl and 267 patients had CD4 count above 500 cells/ µl. Visual acuity of one patient could not be trace back due to data lost.

<table>
<thead>
<tr>
<th>CMV Retinitis</th>
<th>CD4+T Cell count (cell/µl)</th>
<th>Total no.</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt;50</td>
<td>50-99</td>
<td>100-299</td>
</tr>
<tr>
<td>With cmv retinitis</td>
<td>12</td>
<td>9</td>
<td>3</td>
</tr>
<tr>
<td>No cmv retinitis</td>
<td>95</td>
<td>62</td>
<td>119</td>
</tr>
</tbody>
</table>

Table 1: The prevalence of CMV retinitis with different levels of the CD4 T lymphocyte counts
Table 2: CD4 count, duration of ART, Best visual acuity at diagnosis, treatment

<table>
<thead>
<tr>
<th>S. No</th>
<th>Sex</th>
<th>Age (date)</th>
<th>CD4 count (date)</th>
<th>Start of ART</th>
<th>D.O.E</th>
<th>Retinal pathology</th>
<th>VA</th>
<th>Treatment (D.O.T)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1(BE)</td>
<td>M</td>
<td>23</td>
<td>15 (11-03-13)</td>
<td>2.5yrs</td>
<td>28-02-13</td>
<td>CMV(BE)</td>
<td>3m/CF@1m</td>
<td>Valgan (28-02-13)</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>38</td>
<td>38 (08-02-14)</td>
<td>5yrs</td>
<td>11-02-14</td>
<td>CMV(LE)</td>
<td>6/36</td>
<td>Valgan (11-02-14)</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>28</td>
<td>55 (08-01-14)</td>
<td>5.5yrs</td>
<td>05-05-14</td>
<td>CMV + VITRITI S(RE)</td>
<td>HM</td>
<td>Valgan (18-06-14)</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>43</td>
<td>82 (14-02-14)</td>
<td>1yr</td>
<td>16-02-15</td>
<td>CMV(LE)</td>
<td>4/60</td>
<td>Valgan (16-02-15)</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>34</td>
<td>28 (03-11-14)</td>
<td>nil</td>
<td>11-03-15</td>
<td>CMV(LE)</td>
<td>6/60</td>
<td>ART+Valg (18-03-15)</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>30</td>
<td>159 (20-03-15)</td>
<td>1.5Yrs</td>
<td>30-04-15</td>
<td>CMV(LE)</td>
<td>6/12</td>
<td>Valgan (30-04-15)</td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>27</td>
<td>67 (02-03-15)</td>
<td>3months</td>
<td>06-05-15</td>
<td>CMV+VITRITI S</td>
<td>Pl+</td>
<td>Valgan (06-05-15)</td>
</tr>
<tr>
<td>10</td>
<td>M</td>
<td>39</td>
<td>131 (10-01-15)</td>
<td>3yrs</td>
<td>10-06-15</td>
<td>CMV(LE)</td>
<td>CF@1m</td>
<td>Valgan (10-06-15)</td>
</tr>
<tr>
<td>12(BE)</td>
<td>M</td>
<td>47</td>
<td>58 (03-06-13)</td>
<td>Nil</td>
<td>12-06-15</td>
<td>CMV(LE)</td>
<td>CF@3m</td>
<td>ART+Valg (12-06-15)</td>
</tr>
<tr>
<td>13</td>
<td>F</td>
<td>30</td>
<td>35 (29-01-14)</td>
<td>1yr</td>
<td>03-07-15</td>
<td>CMV(LE)</td>
<td>6/60</td>
<td>Valgan (03-07-15)</td>
</tr>
<tr>
<td>14</td>
<td>M</td>
<td>31</td>
<td>129 (31-08-15)</td>
<td>2.5yrs</td>
<td>30-09-15</td>
<td>CMV(LE)</td>
<td>6/36</td>
<td>Valgan (30-09-15)</td>
</tr>
<tr>
<td>15(BE)</td>
<td>M</td>
<td>40</td>
<td>56 (06-10-15)</td>
<td>Nil</td>
<td>08-10-15</td>
<td>CMV(LE)</td>
<td>5/60</td>
<td>ART+Valg (08-10-15)</td>
</tr>
<tr>
<td>16</td>
<td>F</td>
<td>40</td>
<td>48 (26-09-15)</td>
<td>1yr</td>
<td>01-12-15</td>
<td>CMV(LE)</td>
<td>6/24</td>
<td>Valgan (01-12-15)</td>
</tr>
<tr>
<td>17</td>
<td>F</td>
<td>32</td>
<td>05 (14-05-16)</td>
<td>3.5yrs</td>
<td>26-01-16</td>
<td>CMV(LE)</td>
<td>NA</td>
<td>Valgan (26-01-16)</td>
</tr>
<tr>
<td>18</td>
<td>F</td>
<td>40</td>
<td>125 (08-01-16)</td>
<td>2yrs</td>
<td>08-02-16</td>
<td>CMV(LE)</td>
<td>CF@3m</td>
<td>Valgan (08-02-16)</td>
</tr>
<tr>
<td>19</td>
<td>M</td>
<td>40</td>
<td>61 (28-01-16)</td>
<td>5yrs</td>
<td>11-02-16</td>
<td>CMV(LE)</td>
<td>6/60</td>
<td>Valgan (11-02-16)</td>
</tr>
<tr>
<td>20</td>
<td>M</td>
<td>43</td>
<td>68 (31-08-15)</td>
<td>1yr</td>
<td>17-02-16</td>
<td>CMV(LE)</td>
<td>5/60</td>
<td>Valgan (17-02-16)</td>
</tr>
<tr>
<td>21</td>
<td>F</td>
<td>35</td>
<td>46 (07-10-16)</td>
<td>4yrs</td>
<td>09-02-16</td>
<td>CMV(LE)</td>
<td>6/60</td>
<td>Valgan (09-02-16)</td>
</tr>
<tr>
<td>22</td>
<td>M</td>
<td>16</td>
<td>27 (05-04-16)</td>
<td>11yrs</td>
<td>05-04-16</td>
<td>CMV+VITR</td>
<td>HM</td>
<td>Valgan (05-04-16)</td>
</tr>
<tr>
<td>23</td>
<td>M</td>
<td>34</td>
<td>05 (11-02-16)</td>
<td>2month</td>
<td>06-04-16</td>
<td>CMV(LE)</td>
<td>CF@1m</td>
<td>Valgan (06-04-16)</td>
</tr>
<tr>
<td>24(BE)</td>
<td>M</td>
<td>43</td>
<td>06 (31-05-16)</td>
<td>Nil</td>
<td>16-6-16</td>
<td>CMV+ON</td>
<td>PL-</td>
<td>ART+Valg (16-06-16)</td>
</tr>
</tbody>
</table>

Note: BE: Bilateral Eye, LE: Left Eye, RE: Right Eye, CF@1m: Counting Finger at one Meter, HM: hand movement, PL: Perception of Light. D.O.E: Date of examination. D.O.T: Date of Examination, VA visual Acuity. NA : Not available
Discussion

The prevalence of CMV retinitis has declined over the last 5 years as ART has become more widely available and the immune status of patients progressively improved. Previous study by the same author in relation to ocular manifestation in HIV/AIDS, the CMV retinitis was reported 13.8% (12/87) with 8 cases (9.2%) in CD4 Count 51-199 cells/µl and 4 cases (4.6%) in CD4 count less than 50 cells/µl.

Studies recommend systemic screening of CMV retinitis in patients with a CD4 count of <100 cells/µl and mandatory screening practice of patients with absolute CD4 count of <50 cells/mm² or less at the time of diagnosis with or without ocular symptoms aiming at preventing severe visual loss in early stages.6,10,11 Yingna Liu et al found 15.5% (16/103) patients under CD4 count under 100 cells/µl with CMV retinitis, 9 patients reported ocular symptom beforehand similar to present study with 12 patients with ocular symptoms and with 9 patients with visual acuity of worse than Counting Finger in the worse seeing eye (78%, 7/9 had CD4 count <100 of which 4 had level less than 50 count and 22%, 2/9 had CD4 count more than 100 counts).6

Geographically more closure country than mainland India is the Myanmar where notably high prevalence of CMV retinitis (24% CMV retinitis, 211/891) was identified stressing the importance of routine CMV retinitis screening.12 Lack of awareness, limited facilities in remoted areas (more than 70% of state) and associated social sigma are all contributing to the huge submerged iceberg phenomenon in these geographically isolated these part of India.

CMV retinitis remains the most common manifestation of HIV in mainland studies and also its high prevalence suggest implementation of an effective screening procedure in this region and recommend an improvised strategy to increase the more likely hood of a screening procedure.13,7 Lai et al noted that CD4 count lower than 50 cells/mm³ as the single most important risk factor for the development of CMV retinitis, with a hazard ratio of 136 (95% confidence interval, 30–605) and an incidence rate of 3.89/100 person-years.15

In the present study Bilateral CMV retinitis was noted in four patients (0.6%) interestingly all the four had not started Antiretroviral therapy (ART) at the time of diagnosis. Chen C et al in a comparative study noted that number of cases with both eye involvement was more in case of CMV retinitis group (bilateral eye case, 53.66% CMVR) than cases with microvascular retinopathy (MVR) (single eye case, 55.77%).16 The raw proportion of bilateral cases of CMV retinitis in various studies was reported as 42.9% (95% CI, 38.9%–47.0%).17

Fig. 2: Prevalence below and above 100 CD4 cell count

CD4 count lower than 50 cells/mm³ as the single most important risk factor for the development of CMV retinitis, with a hazard ratio of 136 (95% confidence interval, 30–605) and an incidence rate of 3.89/100 person-years.15

In the present study Bilateral CMV retinitis was noted in four patients (0.6%) interestingly all the four had not started Antiretroviral therapy (ART) at the time of diagnosis. Chen C et al in a comparative study noted that number of cases with both eye involvement was more in case of CMV retinitis group (bilateral eye case, 53.66% CMVR) than cases with microvascular retinopathy (MVR) (single eye case, 55.77%).16 The raw proportion of bilateral cases of CMV retinitis in various studies was reported as 42.9% (95% CI, 38.9%–47.0%).17

Fig. 3: Active CMV retinitis

The prevalence of CMV retinitis has declined over the last 5 years as ART has become more widely available and the immune status of patients progressively improved. Previous study by the same author in relation to ocular manifestation in HIV/AIDS, the CMV retinitis was reported 13.8% (12/87) with 8 cases (9.2%) in CD4 Count 51-199 cells/µl and 4 cases (4.6%) in CD4 count less than 50 cells/µl.

Studies recommend systemic screening of CMV retinitis in patients with a CD4 count of <100 cells/µl and mandatory screening practice of patients with absolute CD4 count of <50 cells/mm² or less at the time of diagnosis with or without ocular symptoms aiming at preventing severe visual loss in early stages.6,10,11 Yingna Liu et al found 15.5% (16/103) patients under CD4 count under 100 cells/µl with CMV retinitis, 9 patients reported ocular symptom beforehand similar to present study with 12 patients with ocular symptoms and with 9 patients with visual acuity of worse than Counting Finger in the worse seeing eye (78%, 7/9 had CD4 count <100 of which 4 had level less than 50 count and 22%, 2/9 had CD4 count more than 100 counts).6

Geographically more closure country than mainland India is the Myanmar where notably high prevalence of CMV retinitis (24% CMV retinitis, 211/891) was identified stressing the importance of routine CMV retinitis screening.12 Lack of awareness, limited facilities in remoted areas (more than 70% of state) and associated social sigma are all contributing to the huge submerged iceberg phenomenon in these geographically isolated these part of India.

CMV retinitis remains the most common manifestation of HIV in mainland studies and also its high prevalence suggest implementation of an effective screening procedure in this region and recommend an improvised strategy to increase the more likely hood of a screening procedure.13,7 Lai et al noted that CD4 count lower than 50 cells/mm³ as the single most important risk factor for the development of CMV retinitis, with a hazard ratio of 136 (95% confidence interval, 30–605) and an incidence rate of 3.89/100 person-years.15
Cytomegalovirus retinitis in post HAART era in the north….

Fig. 4: Salt and Pepper irregular pigmentation

Fig. 5: Active CMV retinitis: Irregular white border with satellite lesions

CMV retinitis causes a mixed pattern of visual loss. A decreased visual acuity here means best corrected visual acuity of ≤ 6/12. Despite the reduced in incidence and severity of retinitis in the post Highly active anti-retroviral therapy (HAART) era, studies have affirmed that the ophthalmoscopic appearance of CMV retinitis does not appear to have changed with ocular complications of AIDS in patients with newly diagnosed CMV retinitis in the post-HAART era resembling those prior to the introduction of HAART except for the disease location, severity and immune status. CMV retinitis leading to visual loss is predominately due to maculopathy but its varying degree of vitritis and full thickness involvement can lead to necrosis and retinal breaks and detachments.

In present study, fulminating type of CMV retinitis followed by granular and frosted angitis type was seen in majority of cases. Optic neuritis was seen in one patient. All patients with diagnosed CMV retinitis was started with oral valganciclovir on or within week of diagnosis.

Conclusion

We conclude that prevalence of CMV Retinitis is common in patients with CD4+ T lymphocytes < 50 cells/µl. Ocular symptoms and poor visual acuity may be misleading as sole criteria indicates the presence of CMV retinitis and advocate a systemic screening of all HIV patients with CD4 count < 100 cells/µl to detect the ocular changes due to CMV retinitis for early prevention from severe visual impairment.

Acknowledgement: Thokchom Opendro Singh, Department of Biochemistry for giving valuable input on CMV virual genome and CD 4+ T Lymphocytes.

Conflicting Interest: NIL

References


